CHD, chronic hemodialysis. PMX-DHP, direct hemoperfusion using polymyxin-B immobilized fiber; SOFA score, Sepsis-related organ failure assessment score (excluding the Glasgow Coma Score for most patients under sedation); P/F ratio, partial pressure of oxygen in arterial blood/fraction of inspired oxygen ratio; CaI, catecholamine index. Table 2 .
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ranging from 90 to 1,350 min (327 376 min). We gave nafamostat mesilate as an anticoagulant and maintained the activated clotting time within the range of 180-220 s. We defined life-support devices as percutaneous cardiopulmonary support (PCPS), intra-aortic balloon pumping, continuous hemodiafiltration (CHDF), and HD, and organ failure as a sepsis-related organ failure assessment (SOFA) score of 3 or higher. We defined the catecholamine index (CaI) as the total gamma dosage of dopamine and dobutamine and 100-fold the gamma dosage of adrenaline and noradrenaline. The amounts of catecholamine were compared as the CaI. We compared the patients' age at operation, operation time, extracorporeal circulation time, postoperative course days, PMX-DHP induction time from the beginning of the severe shock state (defined as systolic BP <80 mmHg), the PMX-DHP time, and the number of lifesupport devices in each group. We also compared the SOFA score, excluding the Glasgow Coma Score, for most patients under sedation, the number of failed organs, body temperature, partial pressure of oxygen in the arterial blood/fraction of inspired oxygen ratio (P/F ratio), pH, leukocyte count, C-reactive protein (CRP), hematocrit, platelet count, total bilirubin, creatinine, heart rate, systolic BP, and CaI, immediately before, and 12 h after the PMX-DHP therapy. In those patients who were treated with PMX-DHP more than once, we only studied the data from the first time that PMX-DHP was given. We compared systemic vascular resistance and cardiac output, before and after PMX-DHP, in 12 patients (11 survivors and 1 non-survivor) who had a Swan-Ganz catheter inserted.
Statistical Analysis
All values are expressed as means standard deviation (SD). For normally distributed data, a paired or an unpaired t-test was used. Analyses were performed using the statistical software, Statview 5.0 (SAS Institute, Inc, Cary, NC, USA). A P-value less than 0.05 was considered significant.
Results
There were no significant differences between the survivors and non-survivors in the background factors, age, operation time, extracorporeal circulatory time, postoperative days, PMX-DHP time, time from shock to PMX-DHP induction, or the number of life-support devices ( Table 2) . Just before PMX-DHP was initiated, there were significant differences between the survivors and non-survivors in the SOFA score (9.46 2.84 vs 12.89 3.37; P=0.030, P<0.05, respectively), number of failed organs (1.8 0.9 vs 3.1 1.1; P=0.018, P<0.05), P/F ratio (194 118 vs 102 29; P=0.014, P<0.05), and total bilirubin value (2.7 2.8 mg/dl vs 8.7 6.5 mg/dl; P=0.027, P<0.05). There were no significant differences in body temperature, pH, leukocyte count, CRP, hematocrit, blood platelet, creatinine, heart rate, systolic BP or CaI ( Table 2) .
By 12 h after PMX-DHP, the survivors showed signifi- 
Discussion
Despite remarkable advances in intensive care, the mortality rate associated with septic shock remains high. 3 PMX-DHP is a form of blood purification therapy, initially developed to adsorb blood endotoxins in serious infectious disease states caused by Gram-negative bacteria. Since Aoki et al's report in 1994, 1 PMX-DHP has been used increasingly in Japan for sepsis and septic shock caused by Gram-negative bacterial infections. The adsorption of endotoxin by the polymyxin-B immobilized fiber improves the hemodynamics and prognosis of these patients, but there have been cases of no relationship being found between the endotoxin value and clinical hemodynamics, suggesting the possibility of another mediator. There is also a report of this treatment being used effectively for Gram-positive bacterial infections. 4 Currently, PMX-DHP is initiated to achieve hemodynamic improvement when SIRS caused by infection is diagnosed, regardless of the causative organism. Various theories have been proposed to explain the mechanism of this disease process, and although a consensus has not been reached, it is assumed that a cannabinoid, such as anandamide (ANA), released by monocytes, as well as macrophages, and 2-arachidonyl glycerol (2-AG) produced by the platelets, are all mediators leading to the shock state induced by Gram-negative bacterial infections. 5 In turn, these mediators induce cytokines such as TNF-and IL-1, resulting in the release of highmobility group box 1 (HMGB-1), which is a lethal mediator. PMX-DHP adsorbs the early mediators such as ANA and 2-AG, and the patient's hemodynamics improve in proportion to the absorbed quantity. 6 On the other hand, in a Gram-positive bacterial infection, macrophages pass through a toll-like receptor 2 and are stimulated to produce ANA, which causes hypercytokinemia; 7 in other words, most of the mechanism is shared with that of the endotoxin shock caused by Gram-negative bacterial infection. When the SIRS state caused by infection is diagnosed, it is not necessary to identify the causative organism before initiat- Table 2. ing PMX-DHP. In the past, antiinflammatory drug therapies for septic shock failed to consistently improve the prognosis. 8 PMX-DHP decreases the blood levels of cytokines and improves hemodynamics, 9 so PMX-DHP not only removes endotoxin, but also other cytokines and thus improves the hemodynamics of patients with septic shock. There are many reports of improved clinical symptoms and outcome achieved by PMX-DHP therapy in the septicemic patient, 10 but without clear evidence of its efficacy. A recent pilot study showed that PMX-DHP improved the left ventricular stroke work index, 11 providing further evidence that PMX-DHP improves the hemodynamics of patients in septic shock. Hemocatharsis therapy plays 2 roles in the treatment of sepsis: supporting failing organs such as the kidneys, and treating the disease state itself. The 3 methods of mediator removal are PMX-DHP, high-volume hemofiltration, and plasma exchange. In the present cases, we chose PMX-DHP primarily because it improves the disease state by mediator removal, inducing an immediate effect with simple priming. We diagnosed SIRS caused by postoperative infection in patients unresponsive to vasopressors and instituted PMX-DHP to improve their hemodynamics. Our findings showed clearly that PMX-DHP improved the systolic BP significantly in both the survivors and non-survivors, but reduced the catecholamine level only in the survivors. Ultimately, the results of PMX-DHP were either effective (survival) or ineffective (death), according to differences in the patients' general condition before the initiation of PMX-DHP. Moreover, significant differences were noted between survivors and non-survivors in the SOFA score, the number of failed organs, the P/F ratio, and the total bilirubin concentration. We believe that these differences affected the efficacy of PMX-DHP and the prognosis. There were no significant differences in the platelet count, BP or creatinine levels, so initiating PMX-DHP before lung and liver dysfunction occurs is important for optimizing its efficacy and improving the patient's prognosis. In the 12 patients whose cardiac output and systemic vascular resistance were measured, the cardiac output did not improve, but the systemic vascular resistance improved significantly 12 h after PMX-DHP was initiated. Therefore, we consider that PMX-DHP improves the hemodynamic status not by increasing the cardiac output, but by enhancing systemic vascular resistance. PMX-DHP is an effective radical treatment for septic shock. However, although it was reported that PMX-DHP improved lung function in acute lung injury and acute respiratory distress syndrome, 12 and renal function in combination with CHDF in acute renal failure, 13 those effects were not observed in the present study.
In conclusion, depressed cardiac function resulting from cardiac disturbance during cardiac surgery can easily evolve into multiple organ failure. Therefore, if SIRS related to postoperative infection results in shock that is refractory to vasopressor treatment, PMX-DHP must be initiated with drug treatment before lung and liver dysfunction progresses, in order to achieve optimum efficacy for improving the patient's hemodynamic status and reducing the catecholamine level.
